Deslorelin vs Follistatin 344
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Deslorelin
Potent GnRH super agonist approximately 100× more potent than native GnRH. Used in veterinary medicine for estrus suppression and in human medicine for precocious puberty treatment. In research protocols, used for pituitary desensitization to reset the HPG axis or induce controlled medical suppression of sex hormone production.
Full profileFollistatin 344
Follistatin 344 is a 344-amino acid isoform of follistatin — an endogenous glycoprotein that functions primarily as a myostatin and activin inhibitor. Myostatin (GDF-8) is the body's primary muscle growth suppressor; follistatin binds and neutralizes it with high affinity, removing this brake on muscle protein synthesis. Research and animal data show dramatic increases in muscle fiber size and strength when follistatin is elevated or myostatin is inhibited.
Full profile| Deslorelin | Follistatin 344 | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | SuvaPryn, Ovuplant, D-His6-Pro9-Et-GnRH | FST-344, Follistatin isoform 344, FST |
| Evidence | Research-stage | Research-stage |
| Dosing range | 50mcg–200mcg mcg, Daily SC for continuous suppression; single or short course for pituitary reset | 50mcg–200mcg mcg, Once daily or every other day for 10–30 day cycles |
| Administration | Subcutaneous implant (veterinary), Subcutaneous injection | Subcutaneous injection, Intramuscular injection (into target muscle — local effect hypothesis) |
| Key side effects | Hot flashes, Bone density loss (prolonged suppression), Suppression of testosterone or estrogen, Mood changes, irritability | Potential FSH suppression (reproductive effects in females — may affect menstrual cycle), Accelerated hair follicle cycling (Wnt pathway involvement — theoretical hair loss concern at high doses), Joint discomfort with rapid muscle tissue growth, Limited long-term human safety data |
| Cited sources | 2 references | 3 references |
Key differences
- Administration: Deslorelin — Subcutaneous implant (veterinary), Subcutaneous injection; Follistatin 344 — Subcutaneous injection, Intramuscular injection (into target muscle — local effect hypothesis).
- Frequency: Deslorelin is typically Daily SC for continuous suppression; single or short course for pituitary reset; Follistatin 344 is Once daily or every other day for 10–30 day cycles.
- Research depth: this profile cites 2 sources for Deslorelin vs 3 for Follistatin 344.
How each works
Deslorelin
Deslorelin produces a robust initial LH/FSH surge (flare effect) followed by profound, sustained pituitary desensitization with continued exposure. This biphasic response is consistent across all high-affinity GnRH super agonists. The flare phase is exploited for reproductive timing in veterinary medicine; the desensitization phase creates the clinical suppression used in precocious puberty and research HPG axis reset protocols.
Follistatin 344
Follistatin's muscle effects were dramatically illustrated when mice and cattle with follistatin overexpression or myostatin knockouts developed 2–3x normal muscle mass. Human follistatin gene therapy trials (AAV-mediated) are ongoing for Becker Muscular Dystrophy, showing sustained myostatin inhibition and improved muscle function over years from a single injection. Follistatin also inhibits activin A and B (involved in muscle wasting during illness), FSH secretion (reproductive effects), and inflammatory cytokines. The 344 isoform has an extended heparin-binding domain that increases tissue retention compared to the shorter FST-288 isoform.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.